Aclaris Therapeutics, Inc. has submitted an Investigational New Drug (IND) Application to the U.S. FDA for ATI-450, an oral MK2 inhibitor, for the treatment of rheumatoid arthritis (RA). If the IND is allowed by the FDA, Aclaris plans to initiate a Phase 1 clinical trial of ATI-450 in the second half of 2019.  “We are very pleased to have this IND under review by the FDA,” said Dr. Neal Walker, President & Chief Executive Officer of Aclaris. “We look forward to beginning the development o...